Pasithea Therapeutics (KTTA) Equity Average (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Equity Average for 4 consecutive years, with $17.0 million as the latest value for Q3 2024.
- Quarterly Equity Average fell 46.86% to $17.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $17.0 million through Sep 2024, down 46.86% year-over-year, with the annual reading at $32.9 million for FY2023, 29.84% down from the prior year.
- Equity Average hit $17.0 million in Q3 2024 for Pasithea Therapeutics, down from $18.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $50.7 million in Q1 2022 to a low of $685375.0 in Q2 2021.
- Historically, Equity Average has averaged $30.8 million across 4 years, with a median of $33.0 million in 2021.
- Biggest five-year swings in Equity Average: surged 7290.06% in 2022 and later tumbled 51.74% in 2024.
- Year by year, Equity Average stood at $33.9 million in 2021, then skyrocketed by 31.51% to $44.6 million in 2022, then crashed by 42.02% to $25.9 million in 2023, then crashed by 34.35% to $17.0 million in 2024.
- Business Quant data shows Equity Average for KTTA at $17.0 million in Q3 2024, $18.0 million in Q2 2024, and $21.6 million in Q1 2024.